Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-14 4:27 pm Purchase | 2025-09-30 | 13G | Context Therapeutics Inc. CNTX | Avidity Partners Management LP | 9,200,580 9.900% | 74,404 (+0.82%) | Filing History |
| 2025-11-14 2:27 pm Purchase | 2025-09-30 | 13G | SCYNEXIS, Inc. SCYX | Avidity Partners Management LP | 4,516,757 9.900% | 304,887 (+7.24%) | Filing History |
| 2025-11-14 1:39 pm Sale | 2025-09-30 | 13G | Immunic, Inc. IMUX | Avidity Partners Management LP | 4,699,411 4.800% | -916,400 (-16.32%) | Filing History |
| 2025-11-14 1:33 pm Unchanged | 2025-09-30 | 13G | Kezar Life Sciences, Inc. KZR | Avidity Partners Management LP | 0 0.000% | 0 (Unchanged) | Filing History |
| 2025-08-14 2:37 pm Sale | 2025-06-30 | 13G | Immunic, Inc. IMUX | Avidity Partners Management LP | 5,615,811 5.900% | -425,248 (-7.04%) | Filing History |
| 2025-08-14 2:28 pm Purchase | 2025-06-30 | 13G | Context Therapeutics Inc. CNTX | Avidity Partners Management LP | 9,126,176 9.900% | 1,349,880 (+17.36%) | Filing History |
| 2025-05-15 2:07 pm Sale | 2025-03-31 | 13G | Immunic, Inc. IMUX | Avidity Partners Management LP | 6,041,059 6.600% | -2,981,304 (-33.04%) | Filing History |
| 2025-03-19 9:30 pm Purchase | 2025-03-17 | 13D | Dianthus Therapeutics, Inc. DNTH | Avidity Partners Management LP | 3,378,939 9.900% | 448,689 (+15.31%) | Filing History |
| 2025-02-14 10:42 am Purchase | 2024-12-31 | 13G | Kezar Life Sciences, Inc. KZR | Avidity Partners Management LP | 502,600 6.900% | 55 (+0.01%) | Filing History |
| 2025-02-14 10:26 am Sale | 2024-12-31 | 13G | Perspective Therapeutics, Inc. CATX | Avidity Partners Management LP | 2,841,024 4.200% | -749,402 (-20.87%) | Filing History |
| 2025-02-14 10:21 am Purchase | 2024-12-31 | 13G | SCYNEXIS, Inc. SCYX | Avidity Partners Management LP | 4,211,870 9.900% | 34,667 (+0.83%) | Filing History |
| 2025-02-14 10:16 am Purchase | 2024-12-31 | 13G | Immunic, Inc. IMUX | Avidity Partners Management LP | 9,022,363 9.900% | 32,920 (+0.37%) | Filing History |
| 2025-02-14 10:10 am Sale | 2024-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS | Avidity Partners Management LP | 2,048,020 7.600% | -809,553 (-28.33%) | Filing History |
| 2025-02-14 10:02 am Unchanged | 2024-12-31 | 13G | Context Therapeutics Inc. CNTX | Avidity Partners Management LP | 7,776,296 9.900% | 0 (Unchanged) | Filing History |
| 2024-12-03 9:19 pm Purchase | 2024-11-29 | 13D | Dianthus Therapeutics, Inc. DNTH | Avidity Partners Management LP | 2,930,250 9.900% | 7,427 (+0.25%) | Filing History |
| 2024-11-14 7:38 pm Purchase | 2024-09-30 | 13G | Oruka Therapeutics, Inc. ORKA | Avidity Partners Management LP | 790,926 2.300% | 790,926 (New Position) | Filing History |
| 2024-11-14 7:07 pm Purchase | 2024-09-30 | 13G | SCYNEXIS, Inc. SCYX | Avidity Partners Management LP | 4,177,203 9.900% | 71,993 (+1.75%) | Filing History |
| 2024-11-14 6:14 pm Purchase | 2024-09-30 | 13G | Perspective Therapeutics, Inc. CATX | Avidity Partners Management LP | 3,590,426 5.300% | 3,590,426 (New Position) | Filing History |
| 2024-11-14 6:08 pm Sale | 2024-09-30 | 13G | Caribou Biosciences, Inc. CRBU | Avidity Partners Management LP | 0 0.000% | -6,360,212 (Position Closed) | Filing History |
| 2024-11-14 6:01 pm Sale | 2024-09-30 | 13G | Jasper Therapeutics, Inc. JSPR | Avidity Partners Management LP | 0 0.000% | -760,000 (Position Closed) | Filing History |